Skip to main content

Table 1 DNBC-derived CEIs are associated with tumor response to neoadjuvant chemotherapy in DNBC cohorts

From: Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response

     AUC
cohort regimen patients responders CEI1 CEI2 CEI3 CEI4 CEI5 CEI6
EORTC FEC 37 16 0.73R* 0.57 0.51R 0.61 0.56 0.54
MDA1 TFAC 27 13 0.78 ** 0.62 0.77** 0.61R 0.53 0.61
MDA/MAQC TFAC 30 9 0.77* 0.66 0.78* 0.62R 0.58 0.54
DFCI2 P 24 4 0.73 0.72R 0.50 0.52R 0.52R 0.57R
JBI2 E 43 4 0.85R* 0.73R 0.53 0.88** 0.58R 0.72
  1. Each CEI was evaluated as a univariate predictor of pathological complete response or residual disease using the area under the ROC curve (AUC). Chemotherapy regimens are indicated: A, doxorubicin; C, cyclophosphamide; E, epirubicin; F, 5-fluorouracil; P, either cisplatin or carboplatin; T, either paclitaxel or docetaxel. The CEIs were derived from four independent DNBC cohorts not shown in this table. * P < 0.05; ** P < 0.01. R: AUC is estimated based on association to residual disease (RD).